Papers - Yuki Satoshi
-
A phase II trial of ramucirumab and docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903)
Kawamoto, Y; Sawada, K; Harada, K; Motoo, I; Ando, T; Sogabe, S; Kobayashi, Y; Dazai, M; Nakamura, M; Hatanaka, K; Ishiguro, A; Sato, A; Nakano, S; Shindo, Y; Hosokawa, A; Ito, K; Yoshikawa, A; Ueda, A; Iuchi, K; Yokota, I; Yuki, S; Komatsu, Y
GASTRIC CANCER 29 ( 4 ) 808 - 815 2026.7
-
<i>RAS/BRAF</i> wild-type metastatic high-methylated colorectal cancer has gene expression patterns related to MSI-H and <i>BRAF</i> V600E mutant: a translational research
Wakayama, S; Takahashi, S; Ouchi, K; Sakamoto, Y; Denda, T; Takashima, A; Komatsu, Y; Nakamura, M; Ohori, H; Yamaguchi, T; Kobayashi, Y; Baba, H; Kotake, M; Amagai, K; Kondo, H; Shimada, K; Yamada, Y; Sato, A; Yuki, S; Okita, A; Komine, K; Watanabe, M; Morita, S; Ishioka, C
SCIENTIFIC REPORTS 16 ( 1 ) 2026.3
-
Predictors of the early discontinuation of anamorelin hydrochloride in gastrointestinal cancer-related cachexia: a multicenter retrospective cohort study (HGCSG2201)
Harada, K; Kajiura, S; Sawada, K; Hatanaka, K; Sato, A; Ito, K; Tamura, H; Doi, A; Ando, T; Nakamura, M; Nakatsumi, H; Muranaka, T; Sogabe, S; Ishii, T; Nakano, S; Dazai, M; Sasaki, Y; Kawamoto, Y; Yuki, S; Sakata, Y; Komatsu, Y
SUPPORTIVE CARE IN CANCER 34 ( 3 ) 221 2026.2
-
Results of a phase 2 trial of ramucirumab plus docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903).
Sawada, K; Kawamoto, Y; Harada, K; Ando, T; Sogabe, S; Kobayashi, Y; Dazai, M; Nakamura, M; Hatanaka, K; Ishiguro, A; Sato, A; Nakano, S; Shindo, Y; Hosokawa, A; Ito, K; Yoshikawa, A; Iuchi, K; Yokota, I; Yuki, S; Komatsu, Y
JOURNAL OF CLINICAL ONCOLOGY 43 ( 4_SUPPL ) 447 - 447 2025.2
-
Risk factors for early discontinuation of anamorelin hydrochloride in patients with cancer cachexia: A multicenter, retrospective cohort study (HGCSG2201)
Harada, K; Kajiura, S; Sawada, K; Hatanaka, K; Sato, A; Ito, K; Tamura, H; Doi, A; Ando, T; Nakamura, M; Nakatsumi, H; Muranaka, T; Sogabe, S; Ishii, T; Nakano, S; Dazai, M; Sasaki, Y; Kawamoto, Y; Yuki, S; Komatsu, Y
ANNALS OF ONCOLOGY 35 S207 - S208 2024.6
-
Serum high-sensitivity C-reactive protein and dementia in a community-dwelling Japanese older population (JPSC-AD)
Tachibana, A; Iga, JI; Ozaki, T; Yoshida, T; Yoshino, Y; Shimizu, H; Mori, T; Furuta, Y; Shibata, M; Ohara, T; Hata, J; Taki, Y; Mikami, T; Maeda, T; Ono, K; Mimura, M; Nakashima, K; Takebayashi, M; Ninomiya, T; Ueno, SI; Honda, T; Akiyama, M; Nakaji, S; Murashita, K; Sawada, K; Yokoyama, S; Ishizuka, N; Akasaka, H; Terayama, Y; Yonezawa, H; Takahashi, J; Noguchi-Shinohara, M; Iwasa, K; Yuki-Nozaki, S; Yamada, M; Bun, S; Niimura, H; Shikimoto, R; Kida, H; Fukada, Y; Kowa, H; Nakano, T; Wada, K; Kishi, M; Ishikawa, T; Yuki, S; Fukuhara, R; Koyama, A; Hashimoto, M; Ikeda, M; Kokubo, Y; Uchida, K; Esaki, M; Tatewaki, Y; Thyreau, B; Yonemoto, K; Yoshida, H; Muto, K; Inoue, Y; Ri, I; Momozawa, Y; Terao, C; Kubo, M; Kiyohara, Y
SCIENTIFIC REPORTS 14 ( 1 ) 2024.3
-
HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first line treatment
Harada, K; Nakano, S; Kawamoto, Y; Sawada, K; Miyagishima, T; Sogabe, S; Kobayashi, Y; Ito, K; Sato, A; Yu, C; Dazai, M; Yuki, S; Yokota, I; Komatsu, Y
JOURNAL OF CLINICAL ONCOLOGY 42 ( 3_SUPPL ) 2024.1
-
HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first-line treatment
Sawada, K; Nakano, S; Kawamoto, Y; Miyagishima, T; Sogabe, S; Kobayashi, Y; Ito, K; Sato, A; Chen, Y; Dazai, M; Harada, K; Yuki, S; Yokota, I; Komatsu, Y
ANNALS OF ONCOLOGY 34 S56 - S57 2023.6
-
HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer - Impact of single-heterozygous UGT1A1 on the clinical outcomes
Yuki, S; Ito, K; Harada, K; Kawamoto, Y; Yagisawa, M; Sawada, K; Ishiguro, A; Muto, O; Hatanaka, K; Okuda, H; Sato, A; Sasaki, Y; Nakamura, M; Meguro, T; Dazai, M; Nakatsumi, H; Ueda, A; Sakamoto, N; Sakata, Y; Komatsu, Y
ANNALS OF ONCOLOGY 33 S1449 - S1449 2022.11
-
Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603
Kawamoto, Y; Yuki, S; Sawada, K; Nakamura, M; Muto, O; Sogabe, S; Shindo, Y; Ishiguro, A; Sato, A; Tsuji, Y; Dazai, M; Okuda, H; Meguro, T; Harada, K; Sekiguchi, M; Okada, K; Ito, YM; Sakata, Y; Sakamoto, N; Komatsu, Y
ONCOLOGIST 27 ( 8 ) E642 - E649 2022.8
-
HGCSG1902: Multicenter, prospective, observational study for patients with dysgeusia caused by chemotherapy
Yokoyama, T; Ito, K; Yuki, S; Nakatsumi, H; Ando, T; Sawada, K; Yagisawa, M; Ishiguro, A; Dazai, M; Iwanaga, I; Hatanaka, K; Sato, A; Matsumoto, R; Shindo, Y; Tateyama, M; Muranaka, T; Katagiri, M; Yokota, I; Sakata, Y; Komatsu, Y
ANNALS OF ONCOLOGY 33 S477 - S477 2022.7
-
Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer
Ito, K; Yuki, S; Nakatsumi, H; Kawamoto, Y; Harada, K; Nakano, S; Saito, R; Ando, T; Sawada, K; Yagisawa, M; Ishiguro, A; Dazai, M; Iwanaga, I; Hatanaka, K; Sato, A; Matsumoto, R; Shindo, Y; Tateyama, M; Muranaka, T; Katagiri, M; Yokota, I; Sakata, Y; Sakamoto, N; Komatsu, Y
SUPPORTIVE CARE IN CANCER 30 ( 6 ) 5351 - 5359 2022.6
-
Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201)
Kawamoto, Y; Yuki, S; Meguro, T; Hatanaka, K; Uebayashi, M; Nakamura, M; Okuda, H; Iwanaga, I; Kato, T; Nakano, S; Sato, A; Harada, K; Oba, K; Sakata, Y; Sakamoto, N; Komatsu, Y
ONCOLOGIST 27 ( 5 ) 340 - + 2022.5
-
Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer
Nakano, S; Kawamoto, Y; Yuki, S; Harada, K; Miyagishima, T; Sogabe, S; Dazai, M; Sato, A; Ishiguro, A; Nakamura, M; Kajiura, S; Takahashi, Y; Tateyama, M; Hatanaka, K; Tsuji, Y; Sasaki, T; Shindo, Y; Kobayashi, T; Yokota, I; Sakamoto, N; Sakata, Y; Komatsu, Y
BMJ OPEN 12 ( 5 ) e048833 2022.5
-
HGCSG1902: Multicenter, prospective, observational study for patients with dysgeusia caused by chemotherapy for gastrointestinal cancer
Ito, K; Yuki, S; Nakatsumi, H; Ando, T; Sawada, K; Yagisawa, M; Ishiguro, A; Dazai, M; Iwanaga, I; Hatanaka, K; Sato, A; Matsumoto, R; Shindo, Y; Tateyama, M; Muranaka, T; Katagiri, M; Yokota, I; Sakata, Y; Sakamoto, N; Komatsu, Y
JOURNAL OF CLINICAL ONCOLOGY 40 ( 4 ) 2022.2
-
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of<i> RAS</i> status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial
Denda, T; Takashima, A; Gamoh, M; Iwanaga, I; Komatsu, Y; Takahashi, M; Nakamura, M; Ohori, H; Sakashita, A; Tsuda, M; Kobayashi, Y; Baba, H; Kotake, M; Ishioka, C; Yamada, Y; Sato, A; Yuki, S; Morita, S; Takahashi, S; Yamaguchi, T; Shimada, K
EUROPEAN JOURNAL OF CANCER 154 296 - 306 2021.9
-
HGCSG 1603: A phase 2 trial of ramucirumab plus irinotecan as second-line treatment for advanced gastric cancer
Sawada, K; Kawamoto, Y; Yuki, S; Nakamura, M; Muto, O; Sogabe, S; Shindo, Y; Ishiguro, A; Sato, A; Tsuji, Y; Dazai, M; Okuda, H; Sasaki, T; Harada, K; Nakano, S; Nakatsumi, H; Sekiguchi, M; Sakata, Y; Sakamoto, N; Komatsu, Y
ANNALS OF ONCOLOGY 32 S314 - S314 2021.7
-
Updated results of HGCSG1603: A phase 2 trial of ramucirumab plus irinotecan combination therapy as second-line treatment for patients with advanced gastric cancer
Nakamura, M; Kawamoto, Y; Yuki, S; Sawada, K; Muto, O; Sogabe, S; Shindo, Y; Ishiguro, A; Sato, A; Tsuji, Y; Dazai, M; Okuda, H; Sasaki, T; Harada, K; Nakatsumi, H; Iuchi, K; Sakata, Y; Komatsu, Y
ANNALS OF ONCOLOGY 32 S131 - S131 2021.7
-
HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of second-line treatment after anti-EGFR antibody
Yoshikawa, A; Ito, K; Yuki, S; Kawamoto, Y; Saito, R; Yamamura, T; Yagisawa, M; Ishiguro, A; Muto, O; Hatanaka, K; Okuda, H; Sato, A; Sasaki, Y; Nakamura, M; Sasaki, T; Kobayashi, T; Dazai, M; Nakatsumi, H; Ueda, A; Sakata, Y; Komatsu, Y
ANNALS OF ONCOLOGY 32 S124 - S124 2021.7
-
HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of second-line treatment
Kaneko, S; Ito, K; Yuki, S; Harada, K; Yagisawa, M; Sawada, K; Ishiguro, A; Muto, O; Hatanaka, K; Okuda, H; Sato, A; Sasaki, Y; Nakamura, M; Sasaki, T; Tsuji, Y; Ando, T; Kato, K; Wakabayashi, T; Kotaka, M; Takahashi, Y; Sakata, Y; Komatsu, Y
ANNALS OF ONCOLOGY 32 S125 - S125 2021.7
-
HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of first-line treatment
Ito, K; Yuki, S; Nakano, S; Yagisawa, M; Sawada, K; Ishiguro, A; Muto, O; Hatanaka, K; Okuda, H; Sato, A; Sasaki, Y; Nakamura, M; Sasaki, T; Kobayashi, T; Dazai, M; Nakatsumi, H; Ueda, A; Tateyama, M; Sogabe, S; Matsumoto, R; Sakata, Y; Komatsu, Y
ANNALS OF ONCOLOGY 32 S108 - S108 2021.7
-
Phase II trial of docetaxel and ramucirumab combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer (HGCSG1903).
Saito, R; Kawamoto, Y; Yuki, S; Sogabe, S; Dazai, M; Hosokawa, A; Sawada, K; Sato, A; Nakamura, M; Hatanaka, K; Ishiguro, A; Muto, O; Shindo, Y; Tsuji, Y; Tateyama, M; Ueda, A; Sasaki, T; Katagiri, M; Sakamoto, N; Komatsu, Y
JOURNAL OF CLINICAL ONCOLOGY 39 ( 15 ) 2021.5
-
Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancer
Takahashi, S; Sakamoto, Y; Denda, T; Takashima, A; Komatsu, Y; Nakamura, M; Ohori, H; Yamaguchi, T; Kobayashi, Y; Baba, H; Kotake, M; Amagai, K; Kondo, H; Shimada, K; Sato, A; Yuki, S; Okita, A; Ouchi, K; Komine, K; Watanabe, M; Morita, S; Ishioka, C
CANCER SCIENCE 112 ( 4 ) 1567 - 1578 2021.4
-
Results of a phase II trial of ramucirumab plus irinotecan as second-line treatment for patients with advanced gastric cancer (HGCSG 1603)
Kawamoto, Y; Yuki, S; Sawada, K; Nakamura, M; Muto, O; Sogabe, S; Shindo, Y; Ishiguro, A; Sato, A; Tsuji, Y; Dazai, M; Okuda, H; Sasaki, T; Harada, K; Nakano, S; Nakatsumi, H; Sekiguchi, M; Sakata, Y; Sakamoto, N; Komatsu, Y
JOURNAL OF CLINICAL ONCOLOGY 39 ( 3 ) 2021.1
-
HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first-line treatment.
Nakano, S; Kawamoto, Y; Yuki, S; Harada, K; Sogabe, S; Dazai, M; Sato, A; Ishiguro, A; Nakamura, M; Kajiura, S; Takahashi, Y; Karasaki, H; Tateyama, M; Hatanaka, K; Tsuji, Y; Sasaki, T; Shindo, Y; Kobayashi, T; Sakata, Y; Komatsu, Y
JOURNAL OF CLINICAL ONCOLOGY 38 ( 15 ) 2020.5
-
Analysis of consensus molecular subtypes (CMS) classification in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan (IRI) plus bevacizumab (Bmab) versus mFOLFOX6 or CapeOX plus Bmab as first-line treatment for metastatic colorectal cancer (mCRC)
Yuki, S; Gamoh, M; Denda, T; Takashima, A; Takahashi, S; Nakamura, M; Ohori, H; Yamaguchi, T; Kobayashi, Y; Baba, H; Kotake, M; Amagai, K; Kondo, H; Shimada, K; Sato, A; Ishioka, C; Komine, K; Ouchi, K; Morita, S; Komatsu, Y
JOURNAL OF CLINICAL ONCOLOGY 38 ( 4 ) 2020.2
-
HGCSG 1301: A multicenter, double-blind, randomized controlled phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer treated with IRIS/Bev as second-line therapy-Updated analysis of antitumor efficacy
Ishiguro, A; Nakatsumi, H; Muranaka, T; Kawamoto, Y; Yuki, S; Tateyama, M; Sato, A; Miyagishima, T; Nakamura, M; Dazai, M; Okuda, H; Takahashi, Y; Kobayashi, T; Kato, T; Hatanaka, K; Amano, T; Sakata, Y; Komatsu, Y
JOURNAL OF CLINICAL ONCOLOGY 38 ( 4 ) 2020.2
-
HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P plus GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Tanimoto, A; Yagisawa, M; Nakano, S; Kawamoto, Y; Yuki, S; Ishiguro, A; Takahata, T; Sato, A; Iwanaga, I; Ehira, N; Uebayashi, M; Muto, O; Sasaki, T; Hatanaka, K; Tateyama, M; Wakabayashi, T; Dazai, M; Minami, S; Sakata, Y; Komatsu, Y
ANNALS OF ONCOLOGY 30 2019.11